Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (vol 83, pg 310, 2020)

首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (vol 83, pg 310, 2020)

【24h】

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (vol 83, pg 310, 2020)

机译：Dolutegravir加入抗逆转录病毒治疗 - 幼稚成年人的耐久性效果与HIV-1感染：Gemini-1和Gemini-2随机临床试验96周的结果（Vol 83，PG 310,2020）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《JAIDS: Journal of acquired immune deficiency syndromes》 |2020年第3期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献

1. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (vol 83, pg 310, 2020) [J] . JAIDS: Journal of acquired immune deficiency syndromes . 2020,第3期

机译：Dolutegravir加入抗逆转录病毒治疗 - 幼稚成年人的耐久性效果与HIV-1感染：Gemini-1和Gemini-2随机临床试验96周的结果（Vol 83，PG 310,2020）
2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (vol 393, pg 143, 2019) [J] . Cahn P., Madero J. S., Arribas J. R. The Lancet . 2019,第10167期

机译：DoluteGravir Plus Lamivudine对DoluteGravir加上替替洛维尔 - 野生毒素和Emtrickabine在抗逆转录病毒 - 野生成年人中，患有HIV-1感染（Gemini-1和Gemini-2）：周48个由两种多方形，双盲，随机，非劣势，第3阶段的结果试验（Vol 393，PG 143,2019）
3. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials [J] . Cahn Pedro, Sierra Madero Juan, Ramon Arribas Jose, The Lancet . 2019,第10167期

机译：DoluteGravir Plus Lamivudine对DoluteGravir加上替替洛维尔 - 野生毒素和Emtrickabine在抗逆转录病毒 - 野生成年人中，患有HIV-1感染（Gemini-1和Gemini-2）：周48个由两种多方形，双盲，随机，非劣势，第3阶段的结果审判
4. 2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies [O] . Jean A van Wyk, Choy Y Man, Jörg Sievers, -1

机译：2842.杜鲁格韦（DTG）联合拉米夫定（3TC）的两药疗法（2DR）在未经抗逆转录病毒治疗的未感染HIV-1感染的成年人中在96周的持久效力：GEMINI研究中的亚组分析
5. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials: Erratum [O] . 2020

机译：Dolutegravir加入抗逆转录病毒治疗 - 幼稚成年人的耐用疗效，HIV-1感染：Gemini-1和Gemini-2随机临床试验96周的结果：错误

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (vol 83, pg 310, 2020)

著录项

相似文献

相关主题

期刊订阅